Five-fraction schedule over one week as safe and effective as standard three-week schedule in adjuvant breast radiotherapy
TUESDAY, May 27, 2025 (HealthDay News) — A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive breast cancer who have undergone breast surgery, according to a study presented at the European Society for Radiotherapy and Oncology, held from May 2 to 6 in Vienna.
Adrian M. Brunt, M.B.B.S., from Keele University in Stoke-on-Trent, England, and colleagues randomly assigned 4,110 patients with invasive breast cancer (pT1-3 pN0-1 M0) who had undergone breast surgery to 40 gray in 15 fractions (40Gy/15Fr) over three weeks, 27Gy/5Fr over one week, or 26Gy/5Fr over one week of radiotherapy to the whole breast/chest wall. The primary end point was five-year ipsilateral breast tumor recurrence; follow-up continued to 10 years.
The researchers identified 116 ipsilateral breast tumor recurrences over 10-year follow-up. The shorter radiotherapy schedule provides a similar level of cancer control to standard treatment, with no additional long-term side effects observed. Breast tumor recurrence occurred in 3.6 percent of patients in the 40Gy/15Fr group and in 2.0 percent of patients in the 26Gy/5Fr group, meeting the criteria for noninferiority.
“This 10-year analysis provides definitive long-term evidence that one-week radiotherapy to the breast is a safe, effective, and more practical option for breast cancer patients,” Brunt said in a statement.
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC
Robotic Arm-Assisted TKR Offers Similar Outcome to Conventional TKR
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors